AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$GMAB

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab reported positive Phase III trial results for EPKINLY, Rina-S, and Petosemtamab, potentially expanding patient populations and peak sales to over $5 billion. EPKINLY could address 146,000 patients, Rina-S shows 71% risk reduction in ovarian cancer, and Petosemtamab met endpoints in head and neck cancer. Genmab targets 2027 launches for these treatments.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The announcements could trigger a re‑rating of Genmab's valuation, with analysts likely to raise price targets.

02

Market read

First‑report of pivotal trial data for a listed biotech, high materiality for investors.

03

What to watch

Potential competition in DLBCL and ovarian cancer markets and the company's quiet period ahead of Q3 results.

Relevance 9/10Novelty 9/10Timing: today

Background

Genmab, a Copenhagen‑based biotech, disclosed three positive Phase III trial outcomes for its antibody therapies, outlining large addressable patient populations and peak‑sales forecasts.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab reported positive Phase III readouts for EPKINLY, Rina‑S and petosemtamab, indicating potential 2027 launches and multibillion‑dollar peak‑sales opportunities.

Expected impact

upward pressure as market incorporates strong trial results and expanded addressable populations.

Evidence & confidence

Phase III success is material for a biotech; the company also raised peak‑sales estimates, suggesting significant upside.

Market effects

Sector

Strengthens outlook for antibody‑based oncology therapeutics and may boost related biotech peers.

Regional

Positive for European biotech sector where Genmab is headquartered.

Global

Adds confidence to the broader cancer‑drug pipeline narrative, potentially influencing global biotech sentiment.

Counterpoint

What could challenge this read

If the data are not as robust as presented or regulatory hurdles arise, the stock could face disappointment.

Key entities

  • company
    Genmab A/S

    Biotech firm developing antibody therapies.

Read at source← All news

Related articles

OCT 28
$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com2 min
OCT 28
$GMABHighAI 9/10

Genmab Shares Jump 30% as Head and Neck Cancer Combo Cuts Death Risk by Half

Genmab (GMAB) shares surged 30% after its experimental antibody petosemtamab, combined with Merck's Keytruda, showed a 50% reduction in death risk in a late-stage head and neck cancer trial. The study met both primary endpoints: overall survival and objective response rate. Genmab plans to engage regulators and present full results later. Analysts see potential upside, with an average price target of $94.89, implying 62% upside from recent levels.

finance.biggo.com2 min
OCT 28
$GMABHigh

Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment

Genmab (GMAB) shares surged 30.54% after announcing positive Phase 3 trial results for petosemtamab combined with pembrolizumab in treating head and neck cancer. The treatment showed a 50% reduction in death risk. The company plans to seek regulatory approval. GMAB stock has gained 87.73% year-to-date and 54.3% over the past year. Analysts' average price target is $94.89, suggesting a 62.26% upside.

tipranks.com2 min
OCT 28
$GMABHigh

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab (GMAB) stock rose nearly 30% to an all-time high after positive Phase 3 trial results for its experimental head and neck cancer treatment, Petosemtamab, combined with Merck's Keytruda. The trial met primary goals, showing a 50% reduction in death risk and tripled tumor response odds. The company also reported positive Phase 3 results for its ovarian cancer drug, Rina-S, last week. Retail sentiment on Stocktwits turned bullish.

finance.yahoo.com2 min
OCT 28
$GMABHighAI 8/10

Genmab (GMAB) Stock Surges As Rina-S And Petosemtamab Data Fuel Bull Run

Genmab A/S (GMAB) stock surged 28.9% on October 28, 2026, following positive data for its oncology drugs Rina-S and petosemtamab. The company reported strong Phase 3 results for Rina-S in ovarian cancer and promising Phase 2 data for petosemtamab in colorectal and head and neck cancers. Analysts upgraded GMAB, citing the potential of these drugs, with JPMorgan raising its price target significantly. GMAB's revenue is approximately $21.53B, with a P/E ratio of 155.11.

timothysykes.com2 min